Drugs / E2212
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01221259 | Jan 2010 → Oct 2011 | Alzheimer disease | Eisai Inc. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | E2212 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01221259 ↗ |
| Modality | Small molecule | — CHEMBL2151205 ↗ |
| Route | Oral | “single oral doses of E2212” NCT01221259 ↗ |